



Lung mechanics in pediatric acute respiratory distress syndrome associated to acute COVID-19 and MIS-C: implications for therapies and outcomes

Mecánica pulmonar en el síndrome de distrés respiratorio agudo pediátrico asociado a COVID-19 aguda y MIS-C: implicaciones para las terapias y los resultados

Jesús Domínguez-Rojas^{a,b,c,e}, Álvaro Coronado Muñozⁿ, Yesica Luna-Delgado^d, Giancarlo Alvarado-Gamarra^e, Gaudi Quispe Flores^e, Patrick Caqui-Vilca^h, Noé Atamari-Anahui^f, Cleotilde Mireya Muñoz Ramírez^g, Mariela Tello-Pezoh^h, Pablo Cruces^{c,i,j}, Pablo Vásquez-Hoyos^{c,k,l}, Franco Díaz^{c,i,m}

^aDepartamento de Emergencias y Áreas Críticas. Instituto Nacional de Salud del Niño. Lima, Perú.

^bDivisión de Cuidados Críticos Pediátricos, Hospital Nacional de Emergencias de Villa El Salvador. Lima, Perú.

^cLARed Network, Red Colaborativa Pediátrica de Latinoamérica.

^dDivision de Cuidados Críticos Pediátricos, Hospital Adolfo Guevara Velasco. Cusco, Peru.

^eDepartamento de Pediatría. Hospital Edgardo Rebagliati Martins. Lima, Perú.

^fVicerrectorado de Investigación, Unidad de Investigación para la Generación y Síntesis de Evidencias en Salud, Universidad San Ignacio de Loyola. Lima, Perú.

^gDivisión de Cuidados Críticos Pediátricos, Instituto Nacional de Pediatría. Ciudad de México, México.

^hDepartamento de Pediatría, Instituto Nacional de Salud del Niño San Borja. Lima, Perú.

ⁱUnidad de Cuidados Intensivos Pediátricos, Hospital El Carmen de Maipú. Santiago, Chile.

^jFacultad de Ciencias de la Vida, Universidad Andres Bello. Santiago Chile.

^kDepartamento de Pediatría, Fundación Universitaria de Ciencias de la Salud. Bogotá, Colombia.

^lDepartamento de Pediatría, Universidad Nacional de Colombia. Bogotá, Colombia.

^mEscuela de Medicina, Universidad Finis Terrae. Santiago, Chile.

ⁿDepartment of Pediatrics, McGovern Medical School, University of Texas Health Sciences Center at Houston. Texas, United States.

Received: December 6 2022; Approved: January 23 2023

What do we know about the subject matter of this study?

Pulmonary involvement caused by SARS-CoV-2 in children has different clinical manifestations that could be categorized as pulmonary phenotypes and their recognition could have a potential impact on clinical management.

What does this study contribute to what is already known?

Differences in pulmonary mechanics between MIS-related PARDS and C-related PARDS could contribute to the application of more appropriate ventilation strategies in both groups of critically ill patients.

Correspondence:
Jesús Angel Domínguez Rojas
jesusdominguez24@gmail.com

Edited by:
Francisco Cano Schuffenegger

How to cite this article: Andes pediater. 2023;94(3): XX-XX. DOI: 10.32641/andespediatr.v94i3.4616

Abstract

Objective: To describe lung mechanics in Pediatric Acute Respiratory Distress Syndrome (PARDS) associated with acute COVID-19 and MIS-C with respiratory failure. **Methods:** A concurrent multi-center observational study was performed, analyzing clinical variables and pulmonary mechanics of PARDS associated with COVID-19 in 4 Pediatric intensive care units (PICU) in Peru. The subgroup analysis included PARDS associated with multisystem inflammatory syndrome in children (MIS-C), MIS-PARDS, and PARDS with COVID-19 primary respiratory infection, C-PARDS. In addition, receiver operating characteristic (ROC) curve analysis for mortality and lung mechanics was performed. **Results:** 30 patients were included. The age was 7.5 (4-11) years, 60% were male, and mortality was 23%. 47% corresponded to MIS-PARDS and 53% to C-PARDS groups. C-PARDS had positive RT-PCR in 67% and MIS-PARDS none ($p < 0.001$). C-PARDS group had more profound hypoxemia (P/F ratio < 100 , 86% vs. 38%, $p < 0.01$) and higher driving-pressure [14(10-22) vs 10(10-12) cmH₂O], and lower compliance of the respiratory system (CRS) [0.5 (0.3-0.6) vs 0.7(0.6-0.8) ml/kg/cmH₂O] compared with MIS-PARDS (all $p < 0.05$). The ROC analysis for mortality showed that driving pressure had the best performance [AUC 0.91(95%CI0.81-1.00), with the best cut-off point of 15 cmH₂O (100% sensitivity and 87% specificity). Mortality in C-PARDS was 38% and 7% in MIS-PARDS ($p = 0.09$). MV-free days were 12(0-23) in C-PARDS and 23(21-25) in MIS-PARDS ($p = 0.02$). **Conclusion:** Patients with C-PARDS have lung mechanics characteristics similar to classic moderate to severe PARDS. This was not observed in patients with MIS-C. As seen in other studies, a driving pressure ≥ 15 cmH₂O was the best discriminator for mortality. These findings may help guide ventilatory management strategies for these two different presentations.

Keywords:

PARDS;
COVID-19;
MIS-C;
Pulmonary Mechanics;
Driving Pressure

“Take-home message”

- PARDS associated with acute COVID-19 and MIS-C respiratory failure are two different entities with different lung mechanics.
- C-PARDS group was characterized as a classic moderate to severe PARDS. MIS-PARDS presented a higher gradient between peak pressures and plateau pressures.
- Clinical outcomes revealed that C-PARDS had less VFD and a trend toward higher mortality.
- Data from the quasi-static calculations were associated with mortality; DP ≥ 15 cmH₂O was the best discriminator.

Background

Respiratory failure has been the leading cause of hospital admission and death during the COVID-19 pandemic. Patients develop pneumonia leading to severe acute respiratory distress syndrome (ARDS) which is a frequent cause of admission to intensive care for advanced respiratory support, especially in adult populations¹. However, since the first cohorts' description in China and Europe, many authors reported discrepancies between the severity of the oxygenation and the relatively spared pulmonary mechanics in a subgroup of patients^{2,3}. In addition, atypical lung imaging in chest CT scan and histopathology with lung microvascular involvement raises questions about whether

the underlying pathophysiology in COVID-19 is like that of ARDS in other etiologies^{2,4,5,6}. Thus, a new entity called C-ARDS (COVID-19-associated ARDS) is proposed by some researchers⁷⁻⁹.

Pediatric COVID-19 critical illness is heterogeneous and infrequent¹⁰⁻¹². The most common causes of admission to the pediatric intensive care unit (PICU) are respiratory failure in acute COVID-19 and severe multisystem inflammatory syndrome in children (MIS-C)¹⁰⁻¹⁵. The latter has been associated with different presentations and a large group of patients with MIS-C also have predominantly respiratory failure^{6,16}. While the low morbidity and mortality in the general pediatric population are reassuring, there is a significant gap in knowledge in identifying high-risk subgroups, such as those who develop pediatric ARDS (PARDS) or multiorgan failure^{11,12,17}.

Invasive mechanical ventilation (MV) for pediatric COVID-19 at PICU has been reported between 30% to 70% in different cohorts^{11,13,15,18-20}. For patients with MIS-C and respiratory failure the need for MV has been reported around 15%-18%¹². Surprisingly, specific information on PARDS related to COVID-19 and MIS-C is scarce. The heterogeneous nature of lung involvement generated the hypothesis of distinctive phenotypes in adult C-ARDS based on pulmonary mechanics². Although still controversial, different phenotypes might have implications for therapy and outcomes^{21,22}. This principle also applies to respiratory failure and PARDS secondary to acute COVID-19 and MIS-C. A better description of PARDS characteristics

is urgently needed to improve guidelines and recommendations and ultimately improve outcomes for critically ill children.

This study aimed to describe lung mechanics in critically ill children with PARDS due to COVID-19, analyzing patients with MIS-C with respiratory failure (MIS-PARDS) and severe COVID-19-related PARDS (C-PARDS) and their correlation to clinical outcomes.

Methods

An observational study was conducted in four PICU of pediatric referral hospitals in Perú: *Hospital Nacional Hipolito Unanue*, *Hospital de Emergencias de Villa El Salvador*, *Hospital Regional del Cusco*, and *Hospital Edgardo Rebagliati Martins*. Institutional review boards' approval for data collection was obtained at each hospital, waiving informed consent. The participating sites hospitals included general units with 6-12 beds pr unit, one attending for every 6 beds and 1 nurse for every 2 patients. These units did not have a high-frequency oscillatory ventilator, nitric oxide, extracorporeal membrane oxygenation or renal replacement therapy.

Patients and diagnosis definitions

The study included patients between 1 month and 17 years of age from the pediatric intensive care unit (PICU) Registry of COVID-19 admitted between April 1 and August 31, 2021. Briefly, this observational registry recorded the treatment and the management of critical COVID-19 patients admitted to participating centers. De-identified data were collected from administrative and clinical databases for comparison analysis, including demographics, clinical and physiological parameters, therapeutic interventions, and outcomes. Critical COVID-19 definition included patients with SARS-CoV-2 rt-PCR in respiratory airways or antibody profile compatible with acute COVID-19 infection diagnosed with positive antigen test and CT scan with characteristics of acute COVID-19 infection. In addition, patients who met the case definition for MIS-C according to the United States of America Center for Disease Control were also considered to, to include all the causes of pediatric critical COVID-19, requiring PICU admission, as previously defined^{11,12,23,24}.

Patients with a clinical and microbiological profile of SARS-CoV-2 infection at PICU admission, receiving MV, and meeting the Pediatric Acute Lung Injury Consensus Conference (PALICC) criteria for PARDS²⁵, were included in the analysis. Pneumonia severity was defined based on the Pan American Health Organization (PAHO) definition²⁶. Patients were excluded if they had uncorrected congenital heart disease,

pre-existing lung or airway disease, chronic respiratory failure requiring long-term MV and tracheostomy, left ventricular dysfunction failure with ejection fraction less than 50%²⁷ and COVID-19 with primary neurological involvement. In addition, patients with spontaneous breathing effort and endotracheal tube air leak were excluded due to possible interference data collection and unreliable quasi-static lung mechanics measurements and calculations. Patients were classified into two groups: MIS-PARDS and C-PARDS. All patients with MIS-C diagnostic criteria were classified as MIS-PARDS³¹⁻³³. The C-PARDS group consisted of PARDS patients fulfilling acute COVID-19 pneumonia criteria according to the modified case definitions of the World Health Organization (WHO)³. Supplementary Table 1 shows detailed patient classifications according to diagnostic tests.

Variables and outcomes

During the first 72 hrs after initiation of MV, all patients were screened at 8 AM and 8 PM. PARDS severity was determined following PALICC criteria, according to the oxygenation index, classified as mild (4 to < 8), moderate (8 to < 16), and severe (≥ 16)²⁵. When hypoxemia was the lowest, all the parameters were recorded. Organ dysfunction was assessed by the treating physician based on definitions by the International Pediatric Sepsis Consensus Conference²⁸, and multiorgan dysfunction was defined as ≥ 3 organ dysfunctions. Vasoactive support was quantified through Vasoactive-Inotropic Score (VIS)²⁹. Cardiac function

Table 1. Demographic and clinical characteristics of pediatric respiratory distress syndrome associated with COVID-19 according to the clinical phenotypes and outcome.

	All n. 30	MIS-PARDS n. 14	C-PARDS n. 16
Age, years	7.5 (4-11)	7 (6-9)	10 (2-13)
Male sex	18 (60)	12 (67)*	6 (33)
Weight, kg	30 (21-45)	32 (21-45)	28 (13-57)
Signs and Symptoms			
SpO ₂ , %	87 (82-90)	89 (86-95)*	85 (78-88)
Respiratory distress	24 (80)	12 (86)	12 (75)
Chest Retractions	7 (23)	4 (29)	3 (19)
Oxygen desaturation	21 (70)	7 (50)*	14 (88)
Rhinorrhea	3 (10)	0 (0)	3 (19)
Cough	7 (23)	0 (0)*	7 (44)

Data are n (%) or median (IQR). *p < 0.05 using Fisher's exact test or Mann-Whitney U test. Abbreviations: SpO₂, pulse oximetry saturation; MV, mechanical ventilation; PARDS, Pediatric Acute Respiratory Distress Syndrome; C-PARDS, PARDS associated with COVID-19 pneumonia; MIS-PARDS, PARDS associated with multisystem inflammatory syndrome in children.

was evaluated in all patients with transthoracic echocardiography performed by an experienced clinician, defining cardiac dysfunction as any alteration in systolic and diastolic function, and severe dysfunction was defined as an ejection fraction less than 40%^{27,30}. In assessing organ dysfunction, we consider the worst value in the first 72 h after admission.

Analyzed outcomes were duration of MV, Ventilator-free days at day 30 (VFD), Length of PICU stay, length of hospital stay, multiorgan failure and PICU mortality. VFD was defined as the number of days between weaning off the MV and day 28 after intubation. If the patient dies before day 28 or if the patient requires MV for more than 28-days, the value VFD value was 0. Multiorgan failure was defined as \geq than 3 organ dysfunctions.

Ventilations parameters

Lung mechanics were measured with volume-controlled ventilation (VCV) mode^{34,35}. Ventilator parameters included peak inspiratory pressure (PIP), plateau pressure (Pplat), positive end-expiratory pressure (PEEP), exhaled tidal volume (VTE), and inspiratory time (IT). The arterial blood gases values registered and, additionally, PaO₂/FiO₂ ratio and Oxygenation Index (OI) were calculated. The components of working pressure measured were calculated for each subject, as follows: resistive component (PIP - Pplat) and elastic component, or driving pressure, (DP, Pplat-PEEP). Respiratory system compliance (C_{RS}, mL·cmH₂O⁻¹·kg⁻¹) was calculated according to the standard equation, VTE divided by DP.

Statistical analysis

The data obtained were entered in a database on Microsoft® Excel (version for Windows 2016), re-

viewed, cleaned, and analyzed in STATA v.16 (Stata-Corp LP, Texas, USA). Frequencies and percentages were used to describe the categorical variables, while median and interquartile range (IQR) were used for quantitative data since the assumption of normality was not met. As a secondary analysis we evaluated the lung mechanics parameters and their association with mortality. A p-value less than 0.05 was considered statistically significant. Finally, receiver operator characteristic (ROC) curves were built for DP, C_{RS}, and Pplat, to evaluate their accuracy as discriminators for mortality as an outcome.

Results

During the study period, 123 critically ill COVID-19 children were admitted to the participating units, and 30 of those patients had PARDS and met the selection criteria (figure 1). The median age was 7.5⁴⁻¹¹ years, 63% were intubated before PICU admission and there was a similar distribution between groups, 50% of the patients presented moderate PARDS and 30% severe PARDS (table 1).

Clinical characteristics by diagnosis

According to their COVID-19 diagnosis, 14 (47%) were MIS-PARDS and 16 (53%) were C-PARDS. (Supplementary Table 3). Hemodynamic compromise was seen in all the patients with MIS-PARDS and, in patients with C-PARDS, all but one patient (94%). The oxygen saturation on admission was higher in MIS-PARDS with 89% (86-95) compared with 85% (78-88) in C-PARDS. More patients with MIS-PARDS had some degree of cardiac dysfunction compared with patients within the C-PARDS group (71 vs. 25%, $p = 0.03$), and no other differences were found in organ failures and vasoactive support (Table 2). Mild left ventricular dysfunction was observed in 42% of MIS-PARDS and 6% of C-PARDS (Supplementary Table 2), but no severe dysfunction was observed.

PARDS and Lung mechanics

Severe PARDS was diagnosed in 6 (37%) of patients with C-PARDS compared with 3 (21%) in MIS-PARDS, both groups had 50% of moderate PARDS. The oxygenation index (OI) in MIS-PARDS was 7.5 (4.2-13.6) and in C-PARDS was 11.9 (7.8-23). The tidal volumes, peak pressures and PEEP were slightly higher in C-PARDS compared with MIS-PARDS. The Pplat and the DP were higher in the C-PARDS group. However, the C_{RS} was worst. In the MIS-PARDS group there was a higher PIP to Pplat gradient (table 3 and figure 2).




Figure 1. Study patient flow diagram. (PARDS: Pediatric Acute Respiratory Distress Syndrome; C-PARDS, PARDS associated with COVID-19 pneumonia; MIS-PARDS, PARDS associated with multisystem inflammatory syndrome in children).

Table 2. Organ failure, vasoactive support and clinical outcomes in pediatric respiratory distress syndrome associated with COVID-19 according to the clinical phenotypes and outcomes

	All n. 30	MISC-PARDS n. 14	C-PARDS n. 16
Organ dysfunction			
Pulmonary	30 (100)	14 (100)	16 (100)
Hemodynamic	29 (96)	14 (100)	15 (94)
Another organ (any)	17 (57)	6 (43)	11 (69)
Hematological	10 (33)	3 (21)	7 (44)
Renal	3 (10)	1 (7)	2 (13)
Neurological	6 (20)	3 (21)	3 (19)
GI/Hepatic	3 (10)	2 (14)	1 (6)
Number of organ dysfunctions			
1	5 (17)	2 (14)	3 (19)
2	16 (53)	7 (50)	9 (56)
≥ 3	9 (30)	5 (36)	4 (25)
Vasoactive support			
Any vasoactive	29 (96)	14 (100)	15 (94)
Vasopressor	19 (63)	10 (71)	9 (56)
Inotropes	24 (80)	13 (93)	11 (69)
Median VIS	22 (12-50)	31 (19-50)	18 (10-45)
Outcomes			
Ventilator free days	22 (7-24)	23 (21-25)*	12 (0-23)
PICU length of stay, days	7 (5-9)	6 (5-9)	7 (5-10)
Hospital length of stay, days	11 (7-16)	13 (8-14)	9 (7-18)
ICU death	7 (23)	1 (7)	6 (38)

Data are n (%) or median (IQR). Abbreviations: GI, gastrointestinal; VIS, vasoactive inotropic scale; PARDS: Pediatric Acute Respiratory Distress Syndrome; C-PARDS, PARDS associated with COVID-19 pneumonia; MIS-PARDS, PARDS associated with multisystem inflammatory syndrome in children. PICU: Pediatric Intensive Care Unit.

Clinical outcomes

There was no statistically significant difference in mortality, but there was a higher number of patients that died in the C-PARDS group compared with MIS-PARDS (38% vs. 7%, $p = 0.09$). In both groups, the primary cause of death was refractory shock and multiorgan failure. All the patients had negative cultures for bacterial infection except two patients from the C-PARDS group that died due to bacteremia. One of them had a positive blood culture for viridans streptococci group and the other patient had *Pseudomonas aeruginosa*. The patient with the *Pseudomonas* bacteremia had severe PARDS. Ventilator free days were significantly lower in C-PARDS than MIS-PARDS ($p = 0.02$). C-PARDS had 4 (35%) patients that developed multiorgan failure compared with MIS-PARDS with 5 (36%) patients.

The PICU length of stay was 7^{5-10} days in C-PARDS and 6 (5.9) in MIS-PARDS.

Secondary analysis: Lung mechanics and mortality

There were no significant differences in V_T and PEEP between survivors and non-survivors, but C_{RS} was significantly lower in non-survivors; thus, PIP, Pplat, and DP were higher (all $p < 0.05$). ROC of DP and mortality showed an AUC of 0.91 (95% CI 0.81-1.00), and the best cut point was 15 cmH_2O (100% sensitivity and 87% specificity). AUC for Elastance ($1/C_{RS}$) was 0.89 (95% CI 0.77-1.00), with a best cut-off point was 15 cmH_2O (100% sensitivity and 87% specificity). AUC for Elastance ($1/CRS$) was 0.89 (95% CI 0.77-1.00), with the best cut-off point of 2.7 (CRS 0.37) (85.7% sensibility and 91.3% specificity). AUC for Pplat was 0.89 (95% CI 0.76-1.00), with the best

Table 3. Gas exchange, mechanical ventilation settings, and lung mechanics in pediatric respiratory distress syndrome associated with COVID-19 according to the clinical phenotypes and outcome

	All n. 30	MIS-PARDS n. 14	C-PARDS n. 16
Oxygenation			
FiO ₂	60 (45-100)	53 (40-60)	60 (48-100)
PaO ₂ , mmHg	80 (60-100)	92 (70-129)	77 (55-83)
PaO ₂ /FIO ₂	130 (85-228)	163 (129-252)*	96 (74-150)
PaO ₂ /FIO ₂ < 100	12 (40)	6 (38)*	12 (86)
P(A-a) O ₂ , mmHg	246 (165-399)	235 (141-305)	336 (175-564)
Oxygenation index	9.7 (6.1-19.9)	7.5 (4.2-13.6)*	11.9 (7.8-23.0)
PARDS severity			
Mild (4 to < 8)	6 (20)	4 (29)	2 (13)
Moderate (8 to < 16)	15 (50)	7 (50)	8 (50)
Severe (≥ 16)	9 (30)	3 (21)	6 (37)
Prone Position	9 (30)	3 (21)	6 (38)
Prone duration, hours	48 (48-48)	96 (48-96)	48 (48-48)
Neuromuscular blockade	13 (43)	4 (29)	9 (56)
Arterial Blood Gas			
pH	7.33 (7.19-7.39)	7.30 (7.22-7.39)	7.37 (7.2-7.44)
PaCO ₂ , mmHg	44 (33-51)	38 (33-51)	47 (34-56)
Bicarbonate, mmol/L	21 (17-24)	20 (17-23)	22 (17-26)
Hemoglobin, g/dL	10.3 (9.6-11.0)	10.0 (10.0-11.0)	10.6 (9.0-11.5)
Lactate, mmol/L	1.6 (1.0-3.0)	1.7 (1.2-3.4)	1.4 (0.9-2.6)
Lung mechanics			
PIP, cmH ₂ O	28 (24-32)	27 (22-30)	29 (25-33)
Pplat	20 (16-30)	18 (15-20)*	26 (19-30)
PEEP, cmH ₂ O	7 (6-11)	7 (5-10)	8 (7-12)
Paw	12.7 (11.0-16.4)	11.5 (10.0-16.0)	14.1 (11.6-17.5)
V _T , ml/kg	7 (6-8)	7.0 (6.5-8.0)	6.5 (6.0-7.5)

Data are n (%) or median (IQR); *p < 0.05 using Fisher's exact test or Mann-Whitney U test. Abbreviations: FiO₂: Fraction of inspired oxygen; PaO₂: Arterial oxygen partial pressure; PaO₂/FIO₂: PaO₂ to FiO₂ ratio; P(A-a) O₂: Alveolar-arterial oxygen gradient; PEEP: Positive end-expiratory pressure; PaCO₂: Partial pressure of carbon dioxide; PIP: Peak inspiratory pressure; V_T/Kg: Tidal volume per kilogram; Pplat: plateau pressure; Paw: mean airway pressure; C-ARDS, Coronavirus associated acute respiratory distress syndrome; PARDS: Pediatric Acute Respiratory Distress Syndrome; C-PARDS, PARDS associated with COVID-19 pneumonia; MIS-PARDS, PARDS associated with multisystem inflammatory syndrome in children

cut-off point of 28 (CRS 0.37) (100% sensibility and specificity 87%). (Supplementary Table 4 and supplementary figures).

Discussion

SARS-CoV-2 infection in pediatric patients has two different presentations: acute COVID-19 infection and MIS-C. We examine and describe the lung mechanics in patients that required mechanical ventilation, with

any of these two presentations and PARDS. The lung mechanics parameters were different between subgroups, with a higher elastic component in C-ARDS and a higher resistive component in patients with MIS-ARDS.

The physiopathology of acute COVID-19 and MIS-C is different. However, studies have described overlapping characteristics in MIS-C patients that develop respiratory failure with those with acute COVID-19. These two presentations of respiratory failure secondary to SARS-CoV-2 infection have different physio-




Figure 2. Boxplot graph of calculated parameters of lung mechanics of Children with PARDS associated with COVID-19, according to the clinical phenotypes and outcome. (A) The resistive component of work of breathing (Peak Inspiratory Pressure minus Plateau Pressure subtraction, [PIP-Pplat]); (B) the viscoelastic component of the work of breathing (Driving Pressure, DP); (C) compliance of the respiratory system (C_{RS}). (PARDS: Pediatric Acute Respiratory Distress Syndrome; C-PARDS, PARDS associated with COVID-19 pneumonia; MIS-PARDS, PARDS associated with multisystem inflammatory syndrome in children).

pathology, where the C-PARDS group's features were like a classic moderate to severe primary ARDS. 46 The inherent clinical differences between MIS-C and acute COVID-19 pneumonia may be seen in the presentation of these entities. There is a well-defined group of patients with MIS-C that have a predominantly respiratory presentation as opposed to shock, myocarditis, or Kawasaki-like symptoms. Our inclusion criteria aimed to include patients with MIS-C with such respiratory phenotype and to see if they overlap in lung mechanic characteristics with acute COVID-19. Even excluding patients with moderate and severe left ventricular failure to exclude pulmonary edema caused by left ventricle dysfunction as described in the PARDS criteria, we noticed that the use of vasopressors and mild cardiac dysfunction was more frequent in MIS-C. Both groups had similar length of stay in the PICU, but C-PARDS had lower ventilator free days and higher mortality. Furthermore, the differences in the lung mechanics described point that the possibility that the patients with MIS-C with a predominantly respiratory component are an overlap between acute COVID and MIS-C is unlikely. The C-ARDS numbers with higher driving pressure are consistent with PARDS mechanics and pathophysiology as described by other authors for non-COVID PARDS. However, the MIS-C patients with PARDS had measurements on the ventilator with wider difference between plateau and peak pressure. Remarkably, the DP and C_{RS} of C-PARDS were close to the values reported in other pediatric cohorts of viral PARDS³² and other restrictive lung diseases^{39,11,12,15}. We noticed that the PEEP utilized in C-ARDS seems to be lower than the current recommendations of pediatric ARDS management. Lower PEEP has been associated with higher mortality in ARDS as seen in the study by Khemani et al.⁵⁶. The correlation between physiopathology and this lung mechanics findings needs to be further investigated.

As a secondary analysis we performed a mortality analysis associated with lung mechanics. Our participating centers recorded a historical PARDS mortality of 10% before the the SARS-CoV-2 pandemic. A possible explanation for the trend toward higher mortality is the low C_{RS} of the C-PARDS group, resulting in higher DP, a previous parameter associated with mortality in ARDS patients. In an exploratory analysis, we found that DP was close to the ideal clinical discriminator for mortality. Interestingly, the best cut-off point was 15 cmH₂O, a number mentioned by different authors in other studies. In 2 retrospective studies of children children with MV due to acute hypoxemic respiratory failure, high DP (≥ 15 cmH₂O) was associated with less VFD but not mortality. This threshold has been described in adults as well. Amato et al, in a meta-analysis that included nine prospective trials and more than

3,500 patients, Amato et al. showed that DP was the best variable correlated with survival, even in patients within the usual thresholds of a lung-protective MV strategy⁵¹. Furthermore, interventions that resulted in a decrease in DP were associated with a greater survival rate. Other authors have confirmed the association between DP and ARDS outcomes, and a threshold of 15 cmH₂O, which has been incorporated into most lung-protective protocols^{51,52} and can help understanding the physiopathology, thus leading to a change in the ventilation strategy management when facing these presentations. The mortality of our cohort may seem high when analyzing survival, many studies report a mortality between 10 and 70% in PARDS.³⁷ Our study is a small cohort with critical care patients with COVID-19 or MIS-C and PARDS. It is difficult to draw conclusions regarding mortality compared to other studies. Also, the value of DP associated to mortality needs to be confirmed with larger studies. In addition, there are reports regarding differences in mortality between high and low-middle-income countries^{40,41}.

Our study has some limitations. We report respiratory mechanics in quasi-static conditions in VCV mode; thus, they cannot be extrapolated to other modes of MV with a decelerating flow, which is frequently used in pediatrics⁴⁵. Presented data is the worst during the first 72h of admission, so time-dependent variables are not analyzed⁴⁴. We did not investigate other parameters associated with PARDS severity or outcomes, i.e., dead space or mechanical power, because it was not part of our objective⁵⁴⁻⁵⁶. As in many multicenter studies, there might be differences in ventilatory strategy between hospitals, and comparisons were not possible given the heterogeneity of cases per center. The lack of consistency, especially PEEP titration, might influence some calculations of lung mechanics. The small number of patients in each group might lead to type II statistical errors in some analyzed variables. There is also a risk of type I statistical errors, given the absence of statistical correction for multiple comparisons. Finally, the small number of cases probably influenced the lack of a statistical difference in mortality between C-PARDS and MIS-PARDS groups, although the difference was clinically relevant (38 vs. 7%). Nonetheless, we consider our results important to define high-risk groups of children with critical

COVID-19 and as hypothesis-generating data for PARDS in the general PICU population.

Conclusions

Patients with acute COVID-19 and PARDS have lung mechanics characteristics similar to classic moderate to severe PARDS. Patients with MIS-C and PARDS presented lung mechanics similar to obstructive pulmonary failure. As seen in other studies, a driving pressure ≥ 15 cmH₂O was the best discriminator for mortality. The differences seen help making a clear discrimination between acute COVID-19 and MIS-C with respiratory failure. These findings can help guide ventilation management strategies for these two different presentations.

Ethical Responsibilities

Human Beings and animals protection: Disclosure the authors state that the procedures were followed according to the Declaration of Helsinki and the World Medical Association regarding human experimentation developed for the medical community.

Data confidentiality: The authors state that they have followed the protocols of their Center and Local regulations on the publication of patient data.

Rights to privacy and informed consent: The authors have obtained the informed consent of the patients and/or subjects referred to in the article. This document is in the possession of the correspondence author.

Conflicts of Interest

Authors declare no conflict of interest regarding the present study.

Financial Disclosure

Authors state that no economic support has been associated with the present study.

References

1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395:507-13. DOI: 10.1016/S0140-6736(20)30211-7
2. Luciano Gattinoni, Davide Chiumello, Pietro Caironi. COVID-19 pneumonia: different respiratory treatments for different phenotypes? *Intensive Care Med*. 2020;46(6):1099-102. DOI: 10.1007/s00134-020-06033-2
3. Tsolaki V, Zakyntinos GE, Makris D. The ARDSnet protocol may be detrimental in COVID-19. *Crit Care*. 2020;24:351. DOI: 10.1186/s13054-020-03081-4
4. Hendrickson KW, Peltan ID, Brown SM.

The Epidemiology of Acute Respiratory Distress Syndrome Before and After Coronavirus Disease 2019. *Crit Care Clin.* 2021;37:703-16. DOI: 10.1016/j.ccc.2021.05.001

5. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. *New Engl J Med.* 2020;383:120-8. DOI: 10.1056/NEJMoa2015432
6. Haberecker M, Schwarz EI, Steiger P, et al. Autopsy-Based Pulmonary and Vascular Pathology: Pulmonary Endotheliitis and Multi-Organ Involvement in COVID-19 Associated Deaths. *Respiration.* 2021;1-11. DOI: 10.1159/000518914
7. Marini JJ, Gattinoni L. Management of COVID-19 Respiratory Distress. *JAMA.* 2020;323:2329-30. DOI: 10.1001/jama.2020.6825
8. Pfortmueller CA, Spinetti T, Urman RD, et al. COVID-19-associated acute respiratory distress syndrome (CARDS): Current knowledge on pathophysiology and ICU treatment – A narrative review. *Best Pract Res Clin Anaesthesiol.* 2021;35:351-68. DOI: 10.1016/j.bpa.2020.12.011
9. Acosta MAT, Singer BD. Pathogenesis of COVID-19-induced ARDS: implications for an ageing population. *Eur Respir J.* 2020;56:2002049. DOI: 10.1183/13993003.02049-2020
10. Parcha V, Booker KS, Kalra R, et al. A retrospective cohort study of 12,306 pediatric COVID-19 patients in the United States. *Sci Rep-uk.* 2020;11:10231. DOI: 10.1038/s41598-021-89553-1
11. Gonzalez-Dambrauskas S, Vasquez-Hoyos P, Camporesi A, et al. Pediatric critical COVID-19 and mortality in a multinational cohort. *Medrxiv.* 2021;2021.08.20.21262122. DOI: 10.1101/2021.08.20.21262122
12. Feldstein LR, Tenforde MW, Friedman KG, et al. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. *JAMA.* 2021;325:1074-87. DOI: 10.1001/jama.2021.2091
13. Fislis G, Izard SM, Shah S, et al. Characteristics and risk factors associated with critical illness in pediatric COVID-19. *Ann Intensive Care.* 2020;10:171. DOI: 10.1186/s13613-020-00790-5
14. González-Dambrauskas S, Vásquez-Hoyos P, Camporesi A, et al. Pediatric Critical Care and COVID19. *Pediatrics.* 2020;146:e20201766. DOI: 10.1542/peds.2020-1766
15. Bustos BR, Jaramillo-Bustamante JC, Vasquez-Hoyos P, et al. Pediatric Inflammatory Multisystem Syndrome Associated With SARS-CoV-2: A Case Series Quantitative Systematic Review. *Pediatr Emerg Care.* 2020;37:44-7. DOI: 10.1097/PEC.0000000000002306.
16. Godfred-Cato S, Bryant B, Leung J, et al. COVID-19-Associated Multisystem Inflammatory Syndrome in Children-United States, March-July 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69:1074-80. DOI: <http://dx.doi.org/10.15585/mmwr.mm6932e2>
17. Bourgeois FT, Gutiérrez-Sacristán A, Keller MS, et al. International Analysis of Electronic Health Records of Children and Youth Hospitalized With COVID-19 Infection in 6 Countries. *Jama Netw Open.* 2021;4:e2112596. DOI: 10.1001/jamanetworkopen.2021.12596
18. Kanthimathinathan HK, Buckley H, Lamming C, et al. Characteristics of Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Comparison With Influenza in Children Admitted to U.K. PICUs. *Critical Care Explor.* 2021;3:e0362. DOI: 10.1097/ccc.0000000000000362
19. Chao JY, Derespina KR, Herold BC, et al. Clinical Characteristics and Outcomes of Hospitalized and Critically Ill Children and Adolescents with Coronavirus Disease 2019 (COVID-19) at a Tertiary Care Medical Center in New York City. *J Pediatr.* 2020;223:14-9.e2. DOI: 10.1016/j.jpeds.2020.05.006
20. Lorenzo VB, Nascimento-Carvalho CM. Differences between children with severe acute lower respiratory infection with or without SARS-Cov-2 infection. *J Infection.* 2021;83:e1-e3. DOI: 10.1016/j.jinf.2021.05.038
21. Gattinoni L, Marini JJ. Isn't it time to abandon ARDS? The COVID-19 lesson. *Crit Care.* 2021;25:326. DOI: 10.1186/s13054-021-03748-6
22. Attaway AH, Scheraga RG, Bhimraj A, et al. Severe covid-19 pneumonia: pathogenesis and clinical management. *BMJ.* 2021;372:n436. DOI: 10.1136/bmj.n436
23. Reiff DD, Mannion ML, Samuy N, et al. Distinguishing active pediatric COVID-19 pneumonia from MIS-C. *Pediatr Rheumatol.* 2021;19:21. DOI: 10.1186/s12969-021-00508-2.
24. Rimensberger PC, Kneyber MCJ, Deep A, et al. Caring for Critically Ill Children With Suspected or Proven Coronavirus Disease 2019 Infection: Recommendations by the Scientific Sections' Collaborative of the European Society of Pediatric and Neonatal Intensive Care. *Pediatr Crit Care.* 2020;22:56-67. DOI: 10.1097/ccc.0000000000002599
25. Pediatric Acute Lung Injury Consensus Conference Group. Pediatric acute respiratory distress syndrome: consensus recommendations from the Pediatric Acute Lung Injury Consensus Conference. *Pediatr Crit Care Med.* 2015;16(5):428-39. DOI: 10.1097/PCC.0000000000000350
26. <https://www.paho.org/en/case-definitions-covid-19-surveillance-16-december-2020>
27. Alexander PMA, Checchia PA, Ryerson LM, et al. Cardiovascular Dysfunction Criteria in Critically Ill Children: The PODIUM Consensus Conference. *Pediatrics.* 2022;149:S39-S47. DOI:10.1542/peds.2021-052888f
28. Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. *Pediatr Crit Care Med.* 2005;6(1):2-8. DOI: 10.1097/01.PCC.0000149131.72248.E6.
29. McIntosh AM, Tong S, Deakyn SJ, Davidson JA, Scott HF (2017) Validation of the Vasoactive-Inotropic Score in Pediatric Sepsis. *Pediatr Crit Care Med.* 18(8):750-757. DOI: 10.1097/PCC.0000000000001191.
30. Nagueh SF, Smiseth OA, Appleton CP. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr.* 2016;29(4):277-314. DOI: doi: 10.1016/j.echo.2016.01.011.
31. WHO. Multisystem inflammatory syndrome in children and adolescents with COVID-19. 2020. <https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19>. Accessed December, 15th, 2021.
32. Centers for Disease Control and Prevention. Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-19). Distributed via the CDC Health Alert Network 2020.
33. Royal College of Paediatrics and Child Health. Guidance: Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 2020.
34. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020. World Health Organization. <https://apps.who.int/iris/handle/10665/331446>
35. Cruces P, González-Dambrauskas S, Quilodrán J, et al. Respiratory mechanics in infants with severe bronchiolitis on controlled mechanical ventilation. *BMC Pulm Med.* 2017;17:129. DOI: 10.1186/s12890-017-0475-6
36. Khemani RG, Bart RD, Newth CJL. Respiratory monitoring during

- mechanical ventilation. *Paediatrics and Child Health*. 2007;5(17):193-201. DOI:10.1016/j.paed.2007.02.006
37. Van Schelven P, Koopman AA, Burgerhof J, et al. Driving Pressure Is Associated with Outcome in Pediatric Acute Respiratory Failure. *Pediatr Crit Care Med*. 2022;23(3):e136-44. DOI: 10.1097/PCC.0000000000002848
 38. Schouten LR, Veltkamp F, Bos AP, et al. Incidence and mortality of acute respiratory distress syndrome in children: a systematic review and meta-analysis. *Crit Care Med*. 2016;44(4):819-29. DOI: 10.1097/CCM.0000000000001388
 39. Kim SY, Kim B, Choi SH, et al. Oxygenation Index in the First 24 Hours after the Diagnosis of Acute Respiratory Distress Syndrome as a Surrogate Metric for Risk Stratification in Children. *Acute Critical Care*. 2018;33:222-9. DOI: 10.4266/acc.2018.00136
 40. Munoz AC, Tasayco J, Morales W, et al. High incidence of stroke and mortality in pediatric critical care patients with COVID-19 in Peru. *Pediatr Res*. 2021;1-5. doi: 10.1038/s41390-021-01547-x
 41. Kitano T, Kitano M, Krueger C, et al. The differential impact of pediatric COVID-19 between high-income countries and low- and middle-income countries: A systematic review of fatality and ICU admission in children worldwide. *Plos One*. 2021;16:e0246326. doi: 10.1371/journal.pone.0246326
 42. Panico FF, Troster EJ, Oliveira CS, et al. Risk Factors for Mortality and Outcomes in Pediatric Acute Lung Injury/Acute Respiratory Distress Syndrome. *Pediatr Crit Care Med*. 2015;16:e194-e200. DOI: 10.1097/PCC.0000000000000490
 43. Wong JJM, Lee SW, Tan HL, et al. Lung-Protective Mechanical Ventilation Strategies in Pediatric Acute Respiratory Distress Syndrome. *Pediatr Crit Care Med*. 2020;16(7):e194-200. DOI: 10.1097/PCC.0000000000000490
 44. López-Fernández Y, Azagra AM, Oliva P de la, et al. Pediatric Acute Lung Injury Epidemiology and Natural History Study. *Crit Care Med*. 2021;40:3238-45. DOI: 10.1097/CCM.0b013e318260caa3
 45. Khemani RG, Smith L, Lopez-Fernandez YM, et al. Paediatric acute respiratory distress syndrome incidence and epidemiology (PARDIE): an international, observational study. *Lancet Respir Med*. 2019;7(2):115-28. DOI: 10.1016/S2213-2600(18)30344-8
 46. Weiss SL, Asaro LA, Flori HR, et al. Multiple Organ Dysfunction in Children Mechanically Ventilated for Acute Respiratory Failure. *Pediatr Crit Care Med*. 2017;18:319-29. DOI: 10.1097/PCC.0000000000001091
 47. Pelosi P, D'Onofrio D, Chiumello D, et al. European Respiratory Journal 2003;22:48s-56. DOI: 10.1183/09031936.03.00420803
 48. Ginsburg S, Conlon T, Himebauch A, et al. Left Ventricular Diastolic Dysfunction in Pediatric Sepsis: Outcomes in a Single-Center Retrospective Cohort Study. *Pediatr Crit Care Med*. 2021;22:275-85. doi:10.1097/pcc.0000000000002668
 49. Williams FZ, Sachdeva R, Travers CD, et al. Characterization of Myocardial Dysfunction in Fluid- and Catecholamine-Refractory Pediatric Septic Shock and Its Clinical Significance. *J Intensive Care Med*. 2016;34:17-25. doi:10.1177/0885066616685247
 50. Ranjit S, Aram G, Kisson N, et al. Multimodal Monitoring for Hemodynamic Categorization and Management of Pediatric Septic Shock. *Pediatr Crit Care Med*. 2014;15:e17-e26. doi: 10.1097/pcc.0b013e3182a5589c
 51. Amato MB, Meade MO, Slutsky AS, et al. Driving pressure and survival in the acute respiratory distress syndrome. *N Engl J Med*. 2015;372(8):747-55. DOI: 10.1056/NEJMsa1410639.
 52. Griffiths MJD, McAuley DF, Perkins GD, et al. Guidelines on the management of acute respiratory distress syndrome. *BMJ Open Respiratory Research*. 2019;6:e000420. DOI: 10.1136/bmjresp-2019-000420
 53. Romano MLP, Maia IS, Laranjeira LN, et al. Driving Pressure-limited Strategy for Patients with Acute Respiratory Distress Syndrome. A Pilot Randomized Clinical Trial. *Ann Am Thorac Soc*. 2020;17:596-604. DOI: 10.1513/annalsats.201907-506oc
 54. Diaz F, González-Dambrauskas S, Cristiani F, et al. Driving Pressure and Normalized Energy Transmission Calculations in Mechanically Ventilated Children Without Lung Disease and Pediatric Acute Respiratory Distress Syndrome. *Pediatr Crit Care Med Publish Ahead of Print*. 2021. DOI: 10.1097/pcc.0000000000002780
 55. Bhalla AK, Belani S, Leung D, et al. Higher Dead Space Is Associated with Increased Mortality in Critically Ill Children. *Crit Care Med*. 2015;43:2439-45. DOI: 10.1097/CCM.0000000000001199
 56. Yehya N, Bhalla AK, Thomas NJ, et al. Alveolar Dead Space Fraction Discriminates Mortality in Pediatric Acute Respiratory Distress Syndrome. *Pediatr Crit Care Med*. 2016;17:101-9. DOI: 10.1097/PCC.0000000000000613
 57. Khemani RG, Parvathaneni K, Yehya N, et al. Positive End-Expiratory Pressure Lower Than the ARDS Network Protocol Is Associated with Higher Pediatric Acute Respiratory Distress Syndrome Mortality. *Am J Respir Crit Care Med*. 2018;1:198(1):77-89. doi: 10.1164/rccm.201707-1404OC. PMID: 29373802; PMCID: PMC6034123.